Yusi Chen

Yusi Chen

Auto-generated profile, based on publicly available information

Yusi Chen

Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
BOBabak J Orandi
Babak J Orandi
YCYusi Chen
Yusi Chen
YLYiting Li
Yiting Li
GMGaryn T Metoyer
Garyn T Metoyer
KLKrista L Lentine
Krista L Lentine
MMMara McAdams-DeMarco
Mara McAdams-DeMarco

17 June 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
BOBabak J. Orandi
Babak J. Orandi
YCYusi Chen
Yusi Chen
YLYiting Li
Yiting Li
DCDavid Charyton
David Charyton
KLKrista L Lentine
Krista L Lentine
MMMara McAdams-DeMarco
Mara McAdams-DeMarco
Key Points: GLP-1 receptor agonists (GLP-1 RAs) in diabetes and dialysis are associated with 23% lower mortality and 66% higher chance of transplant waitlisting. GLP-1 RAs are not associated with increased risk of acute pancreatitis, biliary complications, or medullary thyroid cancer. GLP-1 RAs are associated with a 32% increased risk of diabetic retinopathy in patients with diabetes on dialysis. Background: Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis. Methods: In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements (N=6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed. Results: The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m2; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m2. GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses. Conclusions: GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.

26 April 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
YLYiting Li
Yiting Li
GMGayathri Menon
Gayathri Menon
JLJane J. Long
Jane J. Long
YCYusi Chen
Yusi Chen
GMGaryn T. Metoyer
Garyn T. Metoyer
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Key Points: Regardless of race and ethnicity, older adults with kidney failure residing in or receiving care at dialysis facilities located in high-segregation neighborhoods were at a 1.63-fold and 1.53-fold higher risk of dementia diagnosis, respectively. Older adults with kidney failure residing in minority-predominant high-segregation neighborhoods had a 2.19-fold higher risk of dementia diagnosis compared with White individuals in White-predominant neighborhoods. Background: Dementia disproportionately affects older minoritized adults with kidney failure. To better understand the mechanism of this disparity, we studied the role of racial and ethnic segregation (segregation hereafter), i.e., a form of structural racism recently identified as a mechanism in numerous other health disparities. Methods: We identified 901,065 older adults (aged ≥55 years) with kidney failure from 2003 to 2019 using the United States Renal Data System. We quantified dementia risk across tertiles of residential neighborhood segregation score using cause-specific hazard models, adjusting for individual- and neighborhood-level factors. We included an interaction term to quantify the differential effect of segregation on dementia diagnosis by race and ethnicity. Results: We identified 79,851 older adults with kidney failure diagnosed with dementia between 2003 and 2019 (median follow-up: 2.2 years). Compared with those in low-segregation neighborhoods, older adults with kidney failure in high-segregation neighborhoods had a 1.63-fold (95% confidence interval [CI], 1.60 to 1.66) higher risk of dementia diagnosis, an association that differed by race and ethnicity (Asian: adjusted hazard ratio [aHR] = 1.26, 95% CI, 1.15 to 1.38; Black: aHR = 1.66, 95% CI, 1.61 to 1.71; Hispanic: aHR = 2.05, 95% CI, 1.93 to 2.18; White: aHR = 1.59, 95% CI, 1.55 to 1.64; P interaction < 0.001). Notably, older Asian (aHR = 1.76; 95% CI, 1.64 to 1.89), Black (aHR = 2.65; 95% CI, 2.54 to 2.77), Hispanic (aHR = 2.15; 95% CI, 2.04 to 2.26), and White (aHR = 2.20; 95% CI, 2.09 to 2.31) adults with kidney failure residing in minority-predominant high-segregation neighborhoods had a higher risk of dementia diagnosis compared with older White adults with kidney failure in White-predominant high-segregation neighborhoods. Moreover, older adults with kidney failure receiving care at dialysis facilities located in high-segregation neighborhoods also experienced a higher risk of dementia diagnosis (aHR = 1.53; 95% CI, 1.50 to 1.56); this association differed by race and ethnicity ( P interaction < 0.001). Conclusions: Residing in or receiving care at dialysis facilities located in high-segregation neighborhoods was associated with a higher risk of dementia diagnosis among older individuals with kidney failure, particularly minoritized individuals.

22 October 2025 in Clinical Transplantation
Verified
Journal Article
Closed access
GMGaryn Metoyer
Garyn Metoyer
HWHarris Whiteson
Harris Whiteson
YCYusi Chen
Yusi Chen
YLYiting Li
Yiting Li
CGChenxi Gao
Chenxi Gao
BOBabak J. Orandi
Babak J. Orandi

4 March 2024 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
YCYusi Chen
Yusi Chen
YLYiting Li
Yiting Li
YLYi Liu
Yi Liu
BKByoungjun Kim
Byoungjun Kim
JRJessica Moore Ruck
Jessica Moore Ruck
MMMara McAdams-DeMarco
Mara McAdams-DeMarco

18 June 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
YCYusi Chen
Yusi Chen
JLJane J. Long
Jane J. Long
NGNidhi Ghildayal
Nidhi Ghildayal
YLYiting Li
Yiting Li
CGChenxi Gao
Chenxi Gao
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Older (aged ≥55 years) kidney transplant (KT) recipients diagnosed with a sleep disorder after transplantation may be at increased risk for developing dementia. Using the United States Renal Data System/Medicare claims (2010-2020), we identified 16 573 older KT recipients with a functioning graft 1-year post-KT. First-time sleep disorders and newly prescribed sleep medications were ascertained within the first year post-KT. We used cause-specific hazard models to estimate the adjusted hazard ratio of diagnosed dementia with inverse probability of treatment weights. Overall, 3615 (21.8%) KT recipients were newly diagnosed with sleep disorders. Recipients diagnosed with a sleep disorder had a 1.32-fold increased risk for dementia (95% CI:1.15-1.51); those with insomnia had a 1.56-fold increased risk (95% CI:1.20-2.03). Of those diagnosed with insomnia, only 7.5% underwent cognitive behavioral therapy for insomnia. Of the recipients, 12.9% with a sleep disorder were prescribed sleep medications. Recipients prescribed sleep medication had a 1.44-fold increased risk for dementia (95% CI:1.16-1.77). Those prescribed zolpidem, the most commonly prescribed medication (80.1%), had a 1.41-fold increased risk (95% CI:1.12-1.78) for dementia; those prescribed other sleep medications had 3.13-fold (95% CI:1.41-6.98) increased risk for dementia. Post-KT sleep disorders are modifiable dementia risk factors; medication-associated dementia risk should be weighed against other therapies such as cognitive behavioral therapy for insomnia during management.